Treatment of Aging Will Require Combined Therapies, But Haphazard Combination Doesn't Work
A recent study from the Longevity Escape Velocity (LEV) Foundation highlights the necessity of combined therapies for effective aging interventions, challenging the traditional focus on single metabolic manipulations. Researchers, including Brian Kennedy’s team, emphasize that while individual therapies may show modest effects in lifespan extension, their combination often leads to interference rather than synergy. The LEV Foundation’s approach advocates for a rational, damage-repair strategy, targeting multiple forms of age-related damage simultaneously.
The Robust Mouse Rejuvenation (RMR) program serves as a significant case study, demonstrating that combining therapies like rapamycin, senolytics, and gene therapy can yield additive benefits, particularly in enhancing mean lifespan. Although the initial RMR1 study showed promising results, including a rectangularization of the survival curve, it also revealed limitations regarding maximum lifespan extension, prompting a shift to cyclic treatments in future studies.
For professionals in aging research, the LEV Foundation’s findings underscore the importance of strategic combinations in therapeutic development. I encourage you to explore the full article for a deeper understanding of these innovative approaches and their implications for longevity science.